GR-891: a novel 5-fluorouracil acyclonucleoside prodrug for differentiation therapy in rhabdomyosarcoma cells

@article{Marchal1999GR891AN,
  title={GR-891: a novel 5-fluorouracil acyclonucleoside prodrug for differentiation therapy in rhabdomyosarcoma cells},
  author={Juan Antonio Marchal and Jos{\'e} C. Prados and Consolaci{\'o}n Melguizo and Jos{\'e} A. G{\'o}mez and J M Campos and Miguel Angel Gallo and Antonio Espinosa and N. Arena and A. Ar{\'a}nega},
  journal={British Journal of Cancer},
  year={1999},
  volume={79},
  pages={807 - 813}
}
SummaryDifferentiation therapy provides an alternative treatment of cancer that overcomes the undesirable effects of classical chemotherapy, i.e. cytotoxicity and resistance to drugs. This new approach to cancer therapy focuses on the development of specific agents designed to selectively engage the process of terminal differentiation, leading to the elimination of tumorigenic cells and recovery of normal cell homeostasis. A series of new anti-cancer pyrimidine acyclonucleoside-like compounds… 
View on Springer
nature.com
16 Citations
Background Citations
2
Methods Citations
2

16 Citations

Citation Type

Citation Type

Synthesis and evaluation of new 5-fluorouracil antitumor cell differentiating derivatives.
Growth inhibition, G1-arrest, and apoptosis in MCF-7 human breast cancer cells by novel highly lipophilic 5-fluorouracil derivatives
TLDR
Support is provided for the use of these novel compounds as new weapons in the fight against breast cancer by demonstrating induction of apoptosis by the annexin-V-based assay and confirmed using DNA fragmentation analysis on MCF-7 cells.
Expression of multidrug resistance-associated proteins in rhabdomyosarcomas before and after chemotherapy: the relationship between lung resistance-related protein (LRP) and differentiation.
TLDR
The findings indicate that the in vivo expression of LRP, but not of Pgp and MRP-1, is induced by chemotherapeutic treatment in rhabdomyosarcomas, and suggests that LRP plays a role in therapy-induced differentiation.
Multidrug resistance and rhabdomyosarcoma (Review).
TLDR
Although cells exposed to cytotoxic agents increase expression of muscle differentiation markers indicating myogenic differentiation, multidrug resistance may be a major obstacle in differentiation therapy for RMS.
Therapeutic Differentiation of Tumor-derived Insulin-producing Cells Selected for Resistance to Diabetogenic Drugs
TLDR
RINmS cells were found to have higher glucose sensitivity and insulin response compared with parental RINm cells, and experiments suggest that differentiation therapy can be utilized for engineering insulin producing cells with improved defense and secretory mechanisms.
LIGHT, a member of the TNF superfamily, induces morphological changes and delays proliferation in the human rhabdomyosarcoma cell line RD.
TLDR
Findings indicate that LIGHT may be a novel inducer of RD cell differentiation associated with SM alpha-actin expression through the LTbetaR.
Resistance and perspectives in soft tissue sarcomas
TLDR
The current role for chemotherapy in metastatic soft tissue sarcomas is palliative, except for pediatric rhabdomyosarcoma and extraskeletal Ewing’s sarcoma / primitive neuroectodermal tumor, for which cure can be achieved.
Soft tissue sarcoma at the turn of the millennium: aspects of epidemiology, cytogenetics, diagnosis and treatment
TLDR
Soft tissue sarcomas comprise a relatively heterogenic group of malignant tumors arising in mesenchymal tissues and local recurrence rates are relatively high (up to 20%), causing a substantial morbidity.
A topological study of prodrugs of 5-fluorouracil.
Toxin‐based selection of insulin‐producing cells with improved defense properties for islet cell transplantation
  • K. Bloch, P. Vardi
  • Biology, Medicine
    Diabetes/metabolism research and reviews
  • 2005
TLDR
Identifying the mechanisms through which cell defense properties act will help clarify the process responsible for β‐cell regeneration in type I diabetes patients, and possible involvement of different expression of cytoprotective genes in the selection of cell subpopulations, which demonstrate a broad spectrum of resistance.
...
1
2
...

References

SHOWING 1-10 OF 57 REFERENCES
Modulation of the cytotoxic effect of 5-fluorouracil by N-methylformamide on a human colon carcinoma cell line.
TLDR
Immunocytochemical and scanning electron microscopy studies seemed to confirm that the association in which the differentiating agent followed the 5-FU treatment strongly impaired cellular integrity and function and that cytoskeletal elements, particularly microfilaments and surface structures could play an essential role in the mechanisms of cytotoxicity.
Myogenic differentiation of human rhabdomyosarcoma cells induced in vitro by antineoplastic drugs.
TLDR
The effect of various antineoplastic drugs on cell differentiation in vitro was investigated using a human alveolar rhabdomyosarcoma cell clone, RMZ-RC2, and 1-beta-D-arabinofuranosylcytosine and 5-azacytidine were the most effective drugs.
Enhancement of differentiation and cytotoxicity of leukemia cells by combinations of fluorinated pyrimidines and differentiation inducers: development of DNA double-strand breaks.
Chemical modifications on the acyclic moiety of 3-(2-hydroxyethoxy)-1-alkoxypropyl nucleobases. 2. Differentiation and growth inhibition in rhabdomyosarcoma cells after exposure to a novel 5-fluorouracil acyclonucleoside
Combination cytotoxic-differentiation therapy of mouse erythroleukemia cells with 5-fluorouracil and hexamethylene bisacetamide.
TLDR
The combined sequential cytotoxic-differentiation therapy resulting in synergistic cytotoxicity and differentiation may be the basis of a new approach to cancer therapy and may aid in reducing the amounts of chemotherapeutic agents required for effective treatment, while maintaining or even increasing their therapeutic effects.
Differentiation: a suitable strategy for cancer chemotherapy?
TLDR
The in vitro and in vivo effectiveness of the two differentiation agents, in particular retinoic acid (RA) and hexamethylene bisacetamide (HMBA) are compared and the prospects for differentiation therapy as an effective strategy in the treatment and management of malignancy are evaluated.
Differentiation: a suitable strategy for cancer chemotherapy?
TLDR
The in vitro and in vivo effectiveness of the two differentiation agents, in particular retinoic acid (RA) and hexamethylene bisacetamide (HMBA) are compared and the prospects for differentiation therapy as an effective strategy in the treatment and management of malignancy are evaluated.
Therapeutic differentiation in a human rhabdomyosarcoma cell line selected for resistance to actinomycin D
TLDR
The failure of TE.7‐DAC cells to completely re‐enter the program of myogenic differentiation supports the hypothesis that multidrug resistance is a major obstacle in differentiation therapy for RMS.
Low concentrations of actinomycin D potentially cause therapeutic differentiation in human rhabdomyosarcoma cell line RD.
Ara-C treatment leads to differentiation and reverses the transformed phenotype in a human rhabdomyosarcoma cell line.
TLDR
Treatment of this human embryonal RMS cell line with Ara-C results in marked growth inhibition in vitro, loss of tumorigenicity in vivo, and the expression of biochemical markers present in a more differentiated phenotype, suggesting a potential role for differentiation therapy as a therapeutic approach in RMS.
...
1
2
3
4
5
...